Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

RT @biotechfan20: While we wait on $MESO trading halt, remember reproducibility of science. Meso saved lives from COVID ARDS. https://t.co…

While we wait on $MESO trading halt, remember reproducibility of science. Meso saved lives from COVID ARDS. https://t.co/1vzzE1PZDW Independent studies show similar life saving from MSC treated patients. https://t.co/DkRAv4nwnf Maybe tomorrows announ…

$MSB $MESO

Real science is easily duplicated by others. $MESO demonstrated a huge decrease in COVID ARDS mortality. https://t.co/1vzzE1PZDW Scientists independently showed similar mortality improvement in MSC treated patients. https://t.co/DkRAv4nwnf Will Phase…

RT @biotechfan20: Real science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality (huge decrease from SOC) https://t.co/25m68E6oI…

RT @GarciaOlmoD: Real science is replicable! : Cells Vs COVID works! @SanchezGuijoF @marianog65 @FelipeProsper @Red_TerCel @Hospital_FJD @U…

RT @biotechfan20: Real science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality (huge decrease from SOC) https://t.co/25m68E6oI…

👏🏻

RT @biotechfan20: Real science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality (huge decrease from SOC) https://t.co/25m68E6oI…

Real science is replicable! : Cells Vs COVID works! @SanchezGuijoF @marianog65 @FelipeProsper @Red_TerCel @Hospital_FJD @UAM_Medicina https://t.co/xvLrVygR1o

RT @biotechfan20: Real science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality (huge decrease from SOC) https://t.co/25m68E6oI…

$MSB $MESO 🦉

Real science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality (huge decrease from SOC) https://t.co/25m68E6oIZ Replicable by others? Yes. "16% (9/56) in MSC‐treated patients”. https://t.co/DkRAv4nwnf Looking forward to phase 3 trial results.

@Biohazard3737 Please share the basis of thinking. IMO: good science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality. https://t.co/1vzzE1PZDW Replicable by others? Yes. "16% (9/56) in MSC‐treated patients”. https://t.co/DkRAv4nwnf Time w…

RT @biotechfan20: Good science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality. https://t.co/25m68E6oIZ Replicable by others?…

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. https://t.co/JMeobVhGHq

RT @biotechfan20: Good science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality. https://t.co/25m68E6oIZ Replicable by others?…

Good science is replicable. $Meso COVID-19 ARDS at Mt Sinai 17% mortality. https://t.co/25m68E6oIZ Replicable by others? Yes. "16% (9/56) in MSC‐treated patients”. https://t.co/DkRAv4nwnf In science and data I trust,looking forward to phase 3 trial resu…

RT @tripdatabase: New2Trip: Cell-based therapy to reduce mortality from COVID-19: Systematic review & meta-analysis of human studies on acu…

New2Trip: Cell-based therapy to reduce mortality from COVID-19: Systematic review & meta-analysis of human studies on acute respiratory distress syndrome https://t.co/NC7D1gPAha

RT @StemCellsTM: Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respir…

If you found the live interview with Arnold Caplan interesting don't miss this concise review on all cell-based trial to treat Covid-19. https://t.co/nI6i1OW0CR #covid19 #cells https://t.co/2OZbcD6Jf3

Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome https://t.co/7JU2ayCbST

RT @BiotechMania: MSC (間葉系間質細胞) を用いたCOVID-19のARDS治療は今FDAが承認した治験薬が12あるらしい。 https://t.co/wKkSdSGy6D 先日STEM CELLS Translational MedicineにMSCを用…

全て他家のようなので、日本で追随するところも、あまり無茶なことはできないと思いますが...

MSC (間葉系間質細胞) を用いたCOVID-19のARDS治療は今FDAが承認した治験薬が12あるらしい。 https://t.co/wKkSdSGy6D 先日STEM CELLS Translational MedicineにMSCを用いたARDS治療がメタ解析で有望との論文が掲載されたが、ランダム化比較試験 (RCT) をしないと結論は出な…

RT @StemCellsTM: Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respir…

RT @SaludHouse: Las terapias para combatir todo lo que provoca #Covid_19 están saliendo a luz ya con pruebas de seguridad.. una de ellas Cé…

Las terapias para combatir todo lo que provoca #Covid_19 están saliendo a luz ya con pruebas de seguridad.. una de ellas Células Madres. https://t.co/7kgydvYFb5

RT @StemCellsTM: Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respir…

Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome https://t.co/3NiHjg4nFL https://t.co/Qbh8r6A9w3

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. https://t.co/qHElfglFIf

RT @adipose_papers: Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute res…

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. https://t.co/IkKKeSWRyh https://t.co/MsC7SekmAc

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

About this Attention Score

Mentioned by

Readers on